Regeneron’s Pozelimab-BBFG Receives FDA Approval as First Treatment for CHAPLE Disease

The drug Pozelimab can cause life-threatening meningococcal infections, so it is important to get a meningococcal vaccine at least 2 weeks before starting the drug.

It is used to treat a health problem called CD55-deficient protein-losing enteropathy (CHAPLE disease).

Regeneron’s Pozelimab-BBFG Receives FDA Approval as First Treatment for CHAPLE Disease Read More »